Back to News
Competitive LandscapeMarch 2026

Ibudilast in Progressive MS: Why Small Molecule Limitations Demand a Biologic Successor

The SPRINT-MS trial (MediciNova) demonstrated modest neuroprotection with ibudilast, but its non-selective MIF inhibition and off-target PDE effects highlight the ceiling of small-molecule approaches in neuroinflammation.

JFInnova Perspective

JFIN-0001 offers what ibudilast cannot: selective CD74 blockade with no PDE interference, BBB penetration at 12.6 kDa, and a defined mechanism of action — the biologic precision successor the field needs.

References

1
Ibudilast for the treatment of progressive multiple sclerosis (SPRINT-MS): a multicentre, double-blind, randomised, placebo-controlled trial

The Lancet Neurology · 2019

Ibudilast vs VHH neuroinflammation
Share:LinkedInXEmail
PreviousBig Pharma's Shift: Why Sanofi's Recent Acquisitions Validate AI-Driven VHH PlatformsNextNavigating the 2026 FDA Guidelines for AI-Designed Biologics
Back to News